• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤内在免疫相关蛋白可能是某些类型癌症中的新型肿瘤抑制因子。

Tumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer.

机构信息

Center for Disease Prevention Research and Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.

出版信息

Sci Rep. 2019 Jul 29;9(1):10918. doi: 10.1038/s41598-019-47382-3.

DOI:10.1038/s41598-019-47382-3
PMID:31358815
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6662687/
Abstract

Immune checkpoint blockade therapy (ICBT) can unleash T-cell responses against cancer. However, only a small fraction of patients exhibited responses to ICBT. The role of immune checkpoints in cancer cells is not well understood. In this study, we analyzed T-cell coinhibitory/costimulatory genes across more than 1100 samples of the Cancer Cell Line Encyclopedia (CCLE). Nearly 90% of such genes were not expressed or had low expression across the CCLE cancer cell lines. Cell line screening showed the enrichment of cancer cells deprived of the expression of CD27, CEACAM1, CTLA4, LRIG1, PDCD1LG2, or TNFRSF18, suggesting their role as tumor suppressor. The metagene expression signature derived from these six genes - Immu6Metagene was associated with prolonged survival phenotypes. A common set of five oncogenic pathways were significantly inhibited in different types of tumors of the cancer patients with good survival outcome and high Immu6Metagene signature expression. These pathways were TGF-β signaling, angiogenesis, EMT, hypoxia and mitotic process. Our study showed that oncoimmunology related molecules especially the six genes of the Immu6Metagene signature may play the tumor suppressor role in certain cancers. Therefore, the ICBT targeting them should be considered in such context to improve the efficacy.

摘要

免疫检查点阻断疗法 (ICBT) 可以激发针对癌症的 T 细胞反应。然而,只有一小部分患者对 ICBT 有反应。免疫检查点在癌细胞中的作用还不是很清楚。在这项研究中,我们分析了癌症细胞系百科全书 (CCLE) 中超过 1100 个样本中的 T 细胞共抑制/共刺激基因。这些基因中几乎有 90%在 CCLE 癌症细胞系中没有表达或低表达。细胞系筛选显示,缺乏 CD27、CEACAM1、CTLA4、LRIG1、PDCD1LG2 或 TNFRSF18 表达的癌细胞富集,表明它们具有肿瘤抑制作用。从这六个基因中得出的 metagene 表达特征——Immu6Metagene 与延长的生存表型相关。在生存结局良好和 Immu6Metagene 特征表达高的癌症患者的不同类型肿瘤中,一组共同的五种致癌途径被显著抑制。这些途径是 TGF-β 信号通路、血管生成、EMT、缺氧和有丝分裂过程。我们的研究表明,oncogenomics 相关分子,特别是 Immu6Metagene 特征的六个基因,在某些癌症中可能发挥肿瘤抑制作用。因此,在这种情况下,应该考虑针对它们的 ICBT 以提高疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/82df38b927f1/41598_2019_47382_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/d76bcc9822ac/41598_2019_47382_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/7e4660baac51/41598_2019_47382_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/0473e74572ba/41598_2019_47382_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/d8151c373ef7/41598_2019_47382_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/4c5019d84eae/41598_2019_47382_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/82df38b927f1/41598_2019_47382_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/d76bcc9822ac/41598_2019_47382_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/7e4660baac51/41598_2019_47382_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/0473e74572ba/41598_2019_47382_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/d8151c373ef7/41598_2019_47382_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/4c5019d84eae/41598_2019_47382_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e2/6662687/82df38b927f1/41598_2019_47382_Fig6_HTML.jpg

相似文献

1
Tumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer.肿瘤内在免疫相关蛋白可能是某些类型癌症中的新型肿瘤抑制因子。
Sci Rep. 2019 Jul 29;9(1):10918. doi: 10.1038/s41598-019-47382-3.
2
Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy.实体瘤对免疫检查点阻断治疗的固有耐药性。
Cancer Res. 2017 Feb 15;77(4):817-822. doi: 10.1158/0008-5472.CAN-16-2379. Epub 2017 Feb 3.
3
Not All Immune Checkpoints Are Created Equal.并非所有免疫检查点都是平等的。
Front Immunol. 2018 Aug 31;9:1909. doi: 10.3389/fimmu.2018.01909. eCollection 2018.
4
Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy.致癌途径影响抗肿瘤免疫反应和免疫检查点阻断治疗。
Pharmacol Ther. 2018 Jan;181:76-84. doi: 10.1016/j.pharmthera.2017.07.004. Epub 2017 Jul 15.
5
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.靶向缺氧减轻可恢复 T 细胞浸润并使前列腺癌对免疫治疗敏感。
J Clin Invest. 2018 Nov 1;128(11):5137-5149. doi: 10.1172/JCI96268. Epub 2018 Oct 15.
6
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.血管靶向以提高癌症免疫检查点阻断的效率。
Front Immunol. 2018 Dec 21;9:3081. doi: 10.3389/fimmu.2018.03081. eCollection 2018.
7
Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.非编码RNA与免疫检查点——作为癌症治疗手段的临床意义
FEBS J. 2017 Jul;284(13):1952-1966. doi: 10.1111/febs.14030. Epub 2017 Feb 17.
8
Immune checkpoint blockade therapy.免疫检查点阻断疗法。
J Allergy Clin Immunol. 2018 Nov;142(5):1403-1414. doi: 10.1016/j.jaci.2018.02.042. Epub 2018 Mar 27.
9
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.T细胞抑制的细胞内在机制及其在癌症治疗中的应用。
Immunol Rev. 2008 Aug;224:141-65. doi: 10.1111/j.1600-065X.2008.00649.x.
10
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.瘤内 STING 激活与 T 细胞检查点调节产生全身性抗肿瘤免疫。
Cancer Immunol Res. 2017 Aug;5(8):676-684. doi: 10.1158/2326-6066.CIR-17-0049. Epub 2017 Jul 3.

引用本文的文献

1
Analysis of head and neck cancer scRNA-seq data identified PRDM6 promotes tumor progression by modulating immune gene expression.对头颈部癌单细胞RNA测序数据的分析表明,PRDM6通过调节免疫基因表达促进肿瘤进展。
Front Immunol. 2025 Aug 27;16:1596916. doi: 10.3389/fimmu.2025.1596916. eCollection 2025.
2
Analysis of Head and Neck Cancer scRNA-seq Data Identified PRDM6 Promotes Tumor Progression by Modulating Immune Gene Expression.头颈部癌单细胞RNA测序数据分析表明PRDM6通过调节免疫基因表达促进肿瘤进展。
bioRxiv. 2025 Mar 7:2025.03.04.641548. doi: 10.1101/2025.03.04.641548.
3
Non-Canonical Targets of MicroRNAs: Role in Transcriptional Regulation, Disease Pathogenesis and Potential for Therapeutic Targets.

本文引用的文献

1
Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.纳武利尤单抗治疗的非小细胞肺癌患者的超进展性疾病:病例系列。
Thorac Cancer. 2018 Dec;9(12):1782-1787. doi: 10.1111/1759-7714.12894. Epub 2018 Oct 17.
2
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.抗体 Fc/FcR 相互作用在巨噬细胞中作为 PD-1/PD-L1 阻断后非小细胞肺癌发生超进展性疾病的机制。
Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.
3
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
非典型 microRNA 靶标:在转录调控、疾病发病机制中的作用及作为治疗靶点的潜力。
Microrna. 2024;13(2):83-95. doi: 10.2174/0122115366278651240105071533.
4
PES1 reduces CD8 T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma.PES1 通过中断食管鳞状细胞癌中的 ILF3-IL15 复合物来减少 CD8 T 细胞浸润和免疫治疗敏感性。
J Biomed Sci. 2023 Mar 23;30(1):20. doi: 10.1186/s12929-023-00912-8.
5
A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients.一种新型染色质调控相关免疫检查点相关基因预后特征及子宫内膜癌患者的潜在候选药物。
Hereditas. 2022 Oct 18;159(1):40. doi: 10.1186/s41065-022-00253-w.
6
Pancancer Analysis of Revealed as a Biomarker of Prognosis and Immunotherapy.多癌种分析揭示 作为预后和免疫治疗标志物。
Dis Markers. 2022 Sep 9;2022:5447017. doi: 10.1155/2022/5447017. eCollection 2022.
7
Modulation of Lymphocyte Functions in the Microenvironment by Tumor Oncogenic Pathways.肿瘤致癌途径对微环境中淋巴细胞功能的调节。
Front Immunol. 2022 May 19;13:883639. doi: 10.3389/fimmu.2022.883639. eCollection 2022.
8
Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.异常启动子甲基化导致 LRIG1 在基底型/三阴性乳腺癌中沉默。
Br J Cancer. 2022 Aug;127(3):436-448. doi: 10.1038/s41416-022-01812-8. Epub 2022 Apr 19.
9
Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis.免疫检查点与肿瘤转移潜在机制的临床研究
Front Oncol. 2021 Jul 22;11:693321. doi: 10.3389/fonc.2021.693321. eCollection 2021.
10
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.通过 MHC I 类抗原呈递丧失实现癌症免疫逃逸。
Front Immunol. 2021 Mar 9;12:636568. doi: 10.3389/fimmu.2021.636568. eCollection 2021.
抗 PD-1/PD-L1 抑制剂或单药化疗治疗的晚期非小细胞肺癌患者的超进展性疾病。
JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.
4
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.免疫检查点阻断治疗的基本机制。
Cancer Discov. 2018 Sep;8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367. Epub 2018 Aug 16.
5
Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy.肿瘤细胞内在的 PD-1 及其在联合免疫治疗中的意义。
Front Immunol. 2018 Jul 30;9:1774. doi: 10.3389/fimmu.2018.01774. eCollection 2018.
6
Hyperprogression as a distinct outcome after immunotherapy.免疫治疗后出现超进展现象。
Cancer Treat Rev. 2018 Nov;70:16-21. doi: 10.1016/j.ctrv.2018.07.006. Epub 2018 Jul 18.
7
Consistent inverse correlation between DNA methylation of the first intron and gene expression across tissues and species.在不同组织和物种中,第一内含子的 DNA 甲基化与基因表达呈一致的负相关关系。
Epigenetics Chromatin. 2018 Jun 29;11(1):37. doi: 10.1186/s13072-018-0205-1.
8
A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗后迅速进展的腹膜播散性肺腺癌 1 例。
BMC Cancer. 2018 May 31;18(1):620. doi: 10.1186/s12885-018-4549-5.
9
Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.PD-1 抑制剂治疗肛门直肠黑色素瘤的超进展性疾病。
Front Immunol. 2018 Apr 19;9:797. doi: 10.3389/fimmu.2018.00797. eCollection 2018.
10
Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report.单剂量纳武利尤单抗治疗胃癌后照射野内的超进展性疾病:一例报告
Case Rep Oncol. 2018 Mar 7;11(1):143-150. doi: 10.1159/000487477. eCollection 2018 Jan-Apr.